The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model
Open accessAbstract
We aimed to create a prognostic model in metastatic melanoma based on independent prognostic factors in 321 patients receiving interleukin-2 (IL-2)-based immunotherapy with a median follow-up time for patients currently alive of 52 months (range 15-189 months). The patients were treated as part of several phase II protocols and the majority received treatment with intermediate dose subcutaneous IL-2 and interferon-alpha. Neutrophil and monocyte counts, lactate dehydrogenase (LDH), number of metastatic sites, location of metastases and performance status were all statistically significant prognostic factors in univariate analyses. Subsequently, a multivariate Cox's regression analysis identified elevated LDH (P<0.001, hazard ratio 2.8), elevated neutrophil counts (P=0.02, hazard ratio 1.4) and a performance status of 2 (P=0.008, hazard ratio 1.6) as independent prognostic factors for poor survival. An elevated monocyte count could replace an elevated neutrophil count. Patients were assigned to one of three risk groups according to the cumulative risk defined as the sum of simplified risk scores of the three independent prognostic factors. Low-, intermediate- and high-risk patients achieved a median survival of 12.6 months (95% confidence interval (CI), 11.4-13.8), 6.0 months (95% CI, 4.8-7.2) and 3.4 months (95% CI, 1.2-5.6), respectively. The low-risk group encompassed the majority of long-term survivors, whereas the patients in the high-risk group with a very poor prognosis should probably not be offered IL-2-based immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Final Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
Balch, C. M., Soong, S.-J., Gershenwald, J. E., Thompson, J. F., Reintgen, D. S., Cascinelli, N., Urist, M., McMasters, K. M., Ross, M. I., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3622 · Cited by 2,388
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Prognostic factors in 1,521 melanoma patients with distant metastases.
Barth, A., Wanek, L. A., & Morton, D. L. (1995) · PubMed · Cited by 569
Atkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Manola, J., Atkins, M., Ibrahim, J., & Kirkwood, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3782 · Cited by 374
Shamamian, P., Schwartz, J. D., Pocock, B. J. Z., Monea, S., Whiting, D., Marcus, S. G., & Mignatti, P. (2001) · Journal of Cellular Physiology · doi:10.1002/jcp.10014 · Cited by 353
Négrier, S., Escudier, B., Gomez, F., Douillard, J.-Y., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., & Lasset, C. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf257 · Cited by 343
Role of CXCL1 in tumorigenesis of melanoma
Dhawan, P., & Richmond, A. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.72.1.9 · Cited by 303
Role of infiltrated leucocytes in tumour growth and spread
Lin, E. Y., & Pollard, J. W. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601705 · Cited by 278
Metastatic renal carcinoma comprehensive prognostic system
and DGCIN - German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group, Atzpodien, J., Royston, P., Wandert, T., & Reitz, M. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6600768 · Cited by 241
Prognostic factors for survival of patients treated systemically for disseminated melanoma.
Eton, O., Legha, S. S., Moon, T. E., Buzaid, A. C., Papadopoulos, N. E., Plager, C., Burgess, A. M., Bedikian, A. Y., Ring, S., Dong, Q., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.1103 · Cited by 218
Keilholz, U., Conradt, C., Legha, S. S., Khayat, D., Scheibenbogen, C., Thatcher, N., Goey, S. H., Gore, M., Dorval, T., Hancock, B., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.9.2921 · Cited by 194
The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma
Haghnegahdar, H., Du, J., Wang, D., Strieter, R. M., Burdick, M. D., Nanney, L. B., Cardwell, N., Luan, J., Shattuck-Brandt, R., & Richmond, A. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.53 · Cited by 180
Differential response of primary and metastatic melanomas to neutrophils attracted by IL‐8
Schaider, H., Oka, M., Bogenrieder, T., Nesbit, M., Satyamoorthy, K., Berking, C., Matsushima, K., & Herlyn, M. (2003) · International Journal of Cancer · doi:10.1002/ijc.10775 · Cited by 169
Expression and growth-promoting function of the IL-8 receptor β in human melanoma cells
Norgauer, J., Metzner, B., & Schraufstätter, I. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.3.1132 · Cited by 144
Scheibenbogen, C., hler, T. M., Häfele, J., HUNSTEIN, W., & Keilholz, U. (1995) · Melanoma Research · doi:10.1097/00008390-199506000-00006 · Cited by 125
Moser, B., Barella, L., Mattei, S., Schumacher, C., Boulay, F., Colombo, M. P., & Baggiolini, M. (1993) · Biochemical Journal · doi:10.1042/bj2940285 · Cited by 125
Rosenberg, S. A., Yang, J., White, D. E., & Steinberg, S. M. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68669-7 · Cited by 116
Donskov, F. N., Bennedsgaard, K. M., Hokland, M., Marcussen, N., Fisker, R. V., Madsen, H. H. T., Fode, K., & von der Maase, H. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0525-9 · Cited by 42
Schmidt, H., Geertsen, P. F., Fode, K., Rytter, C., Bastholt, L., & von der Maase, H. (2000) · Melanoma Research · doi:10.1097/00008390-200002000-00009 · Cited by 19
Self-citationOverexpression of glut-1 glucose transporter in human breast cancer an immunohistochemical study
(1993) · doi:10.1002/1097-0142(19931115)72:10 · Cited by 1
What do we mean by validating a prognostic model?
(2000) · doi:10.1002/(sici)1097-0258(20000229)19:4<453::aid-sim350>3.0.co;2-5
Cited by
Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types?
Rosales, C. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00113 · Cited by 1,334
Tumour-associated neutrophils in patients with cancer
Shaul, M. E., & Fridlender, Z. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0222-4 · Cited by 1,023
Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer
Sagiv, J. Y., Michaeli, J., Assi, S., Mishalian, I., Kisos, H., Levy, L., Damti, P., Lumbroso, D., Polyansky, L., Sionov, R. V., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.039 · Cited by 816
Teijeira, Á., Garasa, S., Gato, M., Alfaro, C., Migueliz, I., Cirella, A., de Andrea, C., Ochoa, M. C., Otano, I., Etxeberria, I., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.001 · Cited by 788
Tumor-associated neutrophils: friend or foe?
Fridlender, Z. G., & Albelda, S. M. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs123 · Cited by 699
Metadata
- Authors
- Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Larsen, S., Gehl, J., & von der Maase, H.
- Venue
- British Journal of Cancer
- Published
- 2005-07-19
- Volume
- 93
- Issue
- 3
- Pages
- 273-278
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2017381571
- Cited by
- 329
- References
- 28
- FWCI
- 1.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.